A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this SLE study is to evaluate the efficacy, safety and tolerability of two different doses of LY2127399 administered in addition to standard of care therapy in participants with active SLE.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• Clinical diagnosis of SLE as defined by American College of Rheumatology (ACR) criteria

• Have positive antinuclear antibodies (ANA)

• Agree not to become pregnant throughout the course of the trial

• Have a screening SELENA-SLEDAI score ≥6. (The participant must be actively exhibiting all the symptoms scored on the screening SELENA-SLEDAI on the day of screening.)

Exclusion Criteria:

• Have active severe Lupus kidney disease

• Have active Central Nervous System or peripheral neurologic disease

• Have received intravenous immunoglobulin (IVIg) within 180 days of randomization

• Have active or recent infection within 30 days of screening

• Have had a serious infection within 90 days of randomization

• Have evidence or test positive for Hepatitis B

• Have Hepatitis C

• Are human immunodeficiency virus (HIV) positive

• Have evidence of active or latent tuberculosis (TB)

• Presence of significant laboratory abnormalities at screening

• Have had a malignancy in the past 5 years, except for cervical carcinoma in-situ or basal cell or squamous epithelial skin cell that were completely resected with no reoccurrence in the 3 yrs prior to randomization

• Have received greater than 40 mgs of prednisone or equivalent in the past 30 days

• Have changed your dose of antimalarial drug in the past 30 days

• Have changed your dose of immunosuppressive drug in the past 90 days

• Have previously received rituximab